Aristo Bio-Tech and Lifescience
- Market cap
- ₹ 59 Cr.
- P/E
- 8.2x
- P/B
- 1.36x
- 52-week range
- 74.3 – 135
- ROE
- 18%
- ROCE
- 20%
- Dividend yield
- 0.7%
- Debt / equity
- 0.8
- Sector
- Fertilizers & Agrochemicals
- Industry
- Pesticides & Agrochemicals
- Listed on
- NSE SME
About
Aristo Bio-Tech and Lifescience Limited is an India-based agrochemical company. The Company is engaged in the manufacturing, formulation, supplying, packaging and job work services in various pesticides, such as insecticides, herbicides, fungicides, plant growth regulators and a wide variety of other agrochemicals for India, as well as for export. It also exports crop protection products to various countries in finished / packaged goods, as well as bulk. It also provides contract manufacturing, job work and toll manufacturing services and products for reputed Indian and multinational crop protection companies. It has 257 products. Its insecticides crop protection products include Acephate 95% SG; Buprofezin 70% DF; Bifenthrin 2.5 % EC; Bifenthrin 8% SC; Chlorpyrifos 40.8 % EC, and others. The Company supplies its products across 20 states: Assam, Andhra Pradesh, Chhattisgarh, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Kerala, Maharashtra, Odisha, Punjab and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pesticides & Agrochemicals: 33 companies →Aristo Bio-Tech and Lifescience against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)8.2 against a typical 23.3: cheaper than most peers (1st = cheapest).1st of 33
- Sales growth−4.5% against a typical −4.5% from a year earlier.16th of 31
- Profit growth+200% against a typical +15.2% from a year earlier.3rd of 25
- Size₹ 58.6 Cr. market value against a typical ₹ 883.3 Cr. (1st = largest).25th of 31
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil B(Issuer Not Cooperating) | Stable | 6 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Oct 2026 | Rating action | Crisil B(Issuer Not Cooperating) | — | CRISIL | ₹ 10 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 May 2026 | Financial Results/Dividend/Other business matters | ARISTO : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 29, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters. |
| 29 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 14 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters. |
| 29 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
| 14 Nov 2024 | Financial Results/Other business matters | ARISTO : 14-Nov-2024 : The Company has informed the Exchange that a Board meeting to be held on November 13, 2024 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2024, To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| 13 Nov 2024 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 129 | 89 | 133 | 112 | 214 | 104 | 256 | 107 |
| Expenses | 72 | 124 | 85 | 128 | 109 | 206 | 103 | 249 | 99 |
| Operating Profit | 1 | 5 | 4 | 5 | 3 | 8 | 1 | 8 | 8 |
| OPM % | 1.2% | 3.9% | 4.1% | 4% | 2.9% | 3.8% | 1.1% | 3.1% | 8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −1 | 4 | 1 | 4 | 2 | 6 | −1 | 6 | 4 |
| Tax % | −35% | 28% | 13% | 28% | 27% | 25% | −18% | 25% | 27% |
| Net Profit | 0 | 3 | 1 | 3 | 1 | 5 | 0 | 4 | 3 |
| EPS in Rs | −0.48 | 3.8 | 1.47 | 3.78 | 1.94 | 6.68 | −0.72 | 6.13 | 4.42 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 20%
- 5 Years
- 17%
- 3 Years
- 19%
- TTM
- 14%
- 10 Years
- 33%
- 5 Years
- 46%
- 3 Years
- 26%
- TTM
- 77%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 7%
- TTM
- —
- 10 Years
- 16%
- 5 Years
- 14%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aristo Bio-Tech and Lifescience | ₹ 86.00 | ₹ 59 Cr. | 8.2x | 1.4x | 18% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Narendra Singh Barhat
- Chairman of the Board, Managing Director
- Ketankumar Harkantbhai Joshi
- Chief Financial Officer, Whole Time Director
- Ayushi Deora
- Compliance Officer, Company Secretary
- Kusum Narendra Singh Barhat
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.